© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Expert oncologists share updates on the testing and treatment of molecular alterations in advanced non-small cell lung cancer.
April 15th 2022
Expert perspective on the current landscape of actionable mutations and molecular profiling in non–small cell lung cancer management.
Meghan Mooradian, MD, highlights best practices for identifying molecular alterations in NSCLC and addresses barriers to testing.
April 22nd 2022
Insight on the outcomes seen with immunotherapy in non–small cell lung cancer with classical EGFR mutations or ALK rearrangements in the context of clinical study data.
Expert perspective on the poor outcomes observed with immunotherapy in NSCLC with STK11 or KEAP1 mutations, alone or in combination with KRAS alterations.
April 29th 2022
Closing out her discussion on the management of actionable mutations in NSCLC, Meghan Mooradian, MD, highlights the detection and implications of KRAS/TP53 mutations.
May 11th 2022
Expert Ticiana Leal, MD, shares her perspective on routine molecular testing practices in advanced non–small cell lung cancer.
Considerations for optimizing the use of molecular testing in advanced non–small cell lung cancer, addressing insufficient tissue collection and liquid biopsy approaches.
May 18th 2022
After highlighting major barriers to molecular testing in advanced non–small cell lung cancer, Ticiana Leal, MD, provides advice on how to circumvent issues in this setting.
A brief review of the lack of efficacy seen with immunotherapy approaches in patients with EGFR-mutated or ALK-rearranged non–small cell lung cancer.